Please assess the completion status of the following clinical trial:

Trial Title: Pembro+Chemo in Brain Mets

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Non-small cell lunch cancer (NSLC) with untreated asymptomatic brain metastases~* NSLC lacks oncogenic driver mutations~* Absence of new onset neurological symptoms~* Presence of fewer than ten intracranial lesions~* Each lesion measures three centimeters or less~* Life expectancy of greater than three months~* Adequate organ and marrow function~* Ability to understand and willingness to sign a written informed consent document~Exclusion Criteria:~* Presence of oncogenic driver mutations~* Measurable lesion located within 10mm of the optic chiasm or optic nerve, or within the brainstem~* Known leptomeningeal involvement.~* Midline shift~* Serious non-healing wound, ulcer or bone fracture~* Baseline inability to participate or complete neurocognitive testing~* Major surgical procedure (including craniotomy and open brain biopsy) or significant traumatic injury within 14 days prior to registration~* Receipt of a non-CNS minor surgical procedure (e.g. core biopsy or fine needle aspiration) within three days prior to registration~* History of allergic reactions attributed to monoclonal antibodies (mAb), compounds of similar chemical or biologic composition to Pembrolizumab~* Clinically significant cardiovascular disease~* Patients with uncontrolled intercurrent illness~* Patients with psychiatric illness/social situations that would limit compliance with study requirements

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Pembrolizumab with standard of care chemotherapy treatment (Type: EXPERIMENTAL): Patients will receive 200mg or 400mg of Pembrolizumab (standard of care dosing at the discretion of treating physician) over thirty minutes on day 1 every three or six weeks with standard of care chemotherapy treatment (carboplatin, pemetrexed, paclitaxel, nab-paclitaxel).

Based on this trial design, predict the completion outcome and termination type (if applicable).